Merck on Vioxx vs. Celebrex
Executive Summary
Vioxx (rofecoxib) continues to gain share in COX-2 inhibitor market, Merck says. Merck claims to hold a greater than 50% share of the Ob/Gyn, neurology, urology and dental specialty markets, with a 47% share of new prescriptions in the general practitioner market. New prescriptions for Vioxx in June were 900,000, Merck said. The product generated $375 mil. in U.S. sales during the quarter